{"name":"Sichuan Baili Pharmaceutical Co., Ltd.","slug":"sichuan-baili-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"sichuanbaili.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BL-M07D1","genericName":"BL-M07D1","slug":"bl-m07d1","indication":"Indication 1","status":"phase_3"},{"name":"BL-B01D1 for Injection","genericName":"BL-B01D1 for Injection","slug":"bl-b01d1-for-injection","indication":"Phase 2 clinical trials for BL-B01D1 for Injection are ongoing, but specific indications are not publicly available.","status":"phase_2"},{"name":"Nifekalant hydrochloride","genericName":"Nifekalant hydrochloride","slug":"nifekalant-hydrochloride","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"BL-B01D1","genericName":"BL-B01D1","slug":"bl-b01d1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"SI-B001","genericName":"SI-B001","slug":"si-b001","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Liposomal doxorubicin, Paclitaxel or Topotecan","genericName":"Liposomal doxorubicin, Paclitaxel or Topotecan","slug":"liposomal-doxorubicin-paclitaxel-or-topotecan","indication":"Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili)","status":"phase_3"},{"name":"Pemetrexed+Cisplatin or Carboplatin","genericName":"Pemetrexed+Cisplatin or Carboplatin","slug":"pemetrexed-cisplatin-or-carboplatin","indication":"Non-small cell lung cancer (NSCLC), including advanced or metastatic disease","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AP or TP","genericName":"AP or TP","slug":"ap-or-tp","indication":"Major depressive disorder","status":"phase_2"}]}],"pipeline":[{"name":"BL-M07D1","genericName":"BL-M07D1","slug":"bl-m07d1","phase":"phase_3","mechanism":"BL-M07D1 is a small molecule drug that targets the molecular target.","indications":["Indication 1"],"catalyst":""},{"name":"AP or TP","genericName":"AP or TP","slug":"ap-or-tp","phase":"phase_2","mechanism":"Selective serotonin reuptake inhibitor","indications":["Major depressive disorder"],"catalyst":""},{"name":"BL-B01D1","genericName":"BL-B01D1","slug":"bl-b01d1","phase":"phase_3","mechanism":"BL-B01D1 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"BL-B01D1 for Injection","genericName":"BL-B01D1 for Injection","slug":"bl-b01d1-for-injection","phase":"phase_2","mechanism":"BL-B01D1 for Injection is a drug that works by targeting a specific molecular pathway.","indications":["Phase 2 clinical trials for BL-B01D1 for Injection are ongoing, but specific indications are not publicly available."],"catalyst":""},{"name":"Liposomal doxorubicin, Paclitaxel or Topotecan","genericName":"Liposomal doxorubicin, Paclitaxel or Topotecan","slug":"liposomal-doxorubicin-paclitaxel-or-topotecan","phase":"phase_3","mechanism":"This is a combination of three distinct chemotherapy agents—liposomal doxorubicin (intercalates DNA), paclitaxel (stabilizes microtubules), and topotecan (inhibits topoisomerase I)—each with different mechanisms to kill cancer cells.","indications":["Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili)"],"catalyst":""},{"name":"Nifekalant hydrochloride","genericName":"Nifekalant hydrochloride","slug":"nifekalant-hydrochloride","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pemetrexed+Cisplatin or Carboplatin","genericName":"Pemetrexed+Cisplatin or Carboplatin","slug":"pemetrexed-cisplatin-or-carboplatin","phase":"phase_3","mechanism":"Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while cisplatin or carboplatin cross-link DNA, together disrupting cancer cell replication and survival.","indications":["Non-small cell lung cancer (NSCLC), including advanced or metastatic disease","Mesothelioma","Other solid tumors (phase 3 investigational)"],"catalyst":""},{"name":"SI-B001","genericName":"SI-B001","slug":"si-b001","phase":"phase_3","mechanism":"SI-B001 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQWC11cG5laWR5YmFURlZXUUZTMUtpXzV4bFlOdkRjYTJ4OFQwQlNDMndNN1pXNWJLemZhblB4alpvR1NPZWNMNUFSc2lyTi1sWlZKZW5DeWZFSDNoMjlaaTJOMzhUb3VzRU5GVXdYTjZfODJaTUExc0hvUEF4TlMxQkxvYmJEVGhQbnRNZzVnUjh6RktnSDN1eDlGMA?oc=5","date":"2026-03-25","type":"trial","source":"openPR.com","summary":"Recurrent or Metastatic Head and Neck Cancer Clinical Trial - openPR.com","headline":"Recurrent or Metastatic Head and Neck Cancer Clinical Trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOQnVMZjBIMnRadVZZWkJTZGdNU3E0YkV6blU4ZTZwbEVuV09udVJvZDEzTFRmcjhjb1NhRDctNktxUHA1SmViU0xNYVNZejhOUS1XeFJVR3A2VzQ2MjAweE9EdHJJVzhMV0cxYUM0eF9CV0drVXhwbmQ2bHF2YzE5U2M5V0I5cUhtMXdFM1NjckE1dGhXR21uMzBfeWtaWEtkMkdkZnFZd1NDc3NldFFmVndCUEF3elRtNUJGMUpkLWF0UV9ITHpTOURBVS1KY3ZTN24tMWMzMlEyaGdVUXlLZ2JFRE5wWHhUODVFRGxfQlJTSXVkeTMtclBIbXVSQjJEdGxOSHFYdmxvRmtYUDN5RDdIY1NaRmZhQlpORm1oeXo1alRXbzh6SVUzT25SUlhWN3RXMkJJX1dFS2MyTF8wVjZzVGRqNkU?oc=5","date":"2025-10-23","type":"pipeline","source":"prnewswire.com","summary":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight - prnewswire.com","headline":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGtWZHFNbTBHS1YyTU1ENWd4Y09VQ3ZPbWQ2NmZyUHlVbl8zdU5JR1hwbl9aN2xQdlNHaWNSdWV4cjlOdEhHMGVSeEtkaWlVOFN5dGRZZHRHLUN4b1dBUmFGNGVIcWhTTi1NTnNnb00yUDlkLXRzTWVtTFZyT1ozbUtGTmxlUnZzZmEwQkZXSEVIXzR1VkxDWlluLVRXR0tDdTZteTQ0V2ZFbGM3TmJjVWM1TEI4MUlHWnRCOEwydmx6YUtreVMybWJoUWxkSkZtb3dYb1VJNjVLSTdFNWotdGY1ZnlxdnNRWkt1Q2VCeGVvbVpfUWptOXlISkhNZ01FQWF3Zks5YWVJQ0FVYkVpV2x1TnVTdVpK?oc=5","date":"2025-06-09","type":"regulatory","source":"prnewswire.com","summary":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - prnewswire.com","headline":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQOG1CekNpZ1duWUg3aVRzWG0zVFdnTmdTb3hHRVVxSHdsZzJmVDk1VnhSWVBES2NuWjFSdXl5OUI3azZMUFkwdUZ6S1hZMmZibVdLTFBpcHRRUG93SDBJVnFSbXRVdlBqVkEtWVFfM0ZfTFJCTkdpZzhKaFlGcEhPM1BnUFk4WE53c1BqSkhoa1F3WTJ3QjM4VmthVHhsWFVfRXlvbnc5RUEzWWtQaHVXTHAxNl9fOG1hcG03bjNtZXg0NXQtTnF4dXk4TkpkMC1lOU1xTy1RbzdtMGhHRkZTRmZIS0pYMXdVcmhjYk95ODZzZWdzYXc?oc=5","date":"2024-10-08","type":"pipeline","source":"prnewswire.com","summary":"CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight - prnewswire.com","headline":"CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOQnl2Q0VYNjRxOFJEenBtbHZfNkFHeTcyUjRlVHIxS1pHLVg1SkM0QllMcUJsSl9Md1pfOHktSXdKN0pya0lYbmhLdzdTZUZTZUxiMjFIMXFfUkJCanFJaE5YVWdWUXpjVkU2NFBMLWl6RkV3RmRiYmJ1Wk5ramVuRFF0Q2hhWW8wZjZDUFJxYlQ3aVktWjlpUWFESVh2R2RZVzNSV0ZXR290bWQzaUo2SGtQSUd3WE1BMUFrYldtSDg2ajFteVY5MFFsVTY?oc=5","date":"2023-12-11","type":"pipeline","source":"Reuters","summary":"Bristol Myers to pay $800 million to Chinese drugmaker to develop cancer drug - Reuters","headline":"Bristol Myers to pay $800 million to Chinese drugmaker to develop cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxORmREbWNJelp6ZXlnLXdmRHoxSTZtMThKUjE2b01fV2NOR05ZdWhJcENIOEtDakZLOTNJS0sxRVpyZDN3eEg4bzgtNzVlTjloeEhOcE82aE84WmMwME5lYXktZXNHSlJseTQteTFGVmRaMFNqbmx1T2hQcFNIMDhHbnhTek9kZWh6NFVWb2RLeUY4RUhwV0VZd3NmLW5rdWZkZUplZUR0UkF1ODVIVW9IM2NuS05qSEFUV0p1bHpjNkN6UVdCSnlqV0lhVGdKYVlmZHJUbW9aclVpLWVEVHFCSFZWSWQzdkQ4NjlKU29FOTVuXzA0d0RrbQ?oc=5","date":"2023-11-21","type":"trial","source":"prnewswire.com","summary":"Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight - prnewswire.com","headline":"Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBJUFlvTUl4YVRSZGFQUDg4Um9GTVg2dHZaQkFyTllGazhRckVhbm1LNXhxUUxMQ0FyVFhOenlJS3h4QmhTNlhpVnJ2T0w3ZEYwTEh6a0JOSFY?oc=5","date":"2023-07-02","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE5HeGNHSnpWV2t6Vk04MUVEblZKRmlxbUpHV1hvNUF6MTluWlRhUkhEdmgtaDZtSmtOaWdkc3VKUlU4TWFib25COTNIVEdXM0l6ejlGWTlpRzBiOUU?oc=5","date":"2023-01-05","type":"pipeline","source":"TradingView","summary":"688506 Stock Price and Chart — SSE:688506 - TradingView","headline":"688506 Stock Price and Chart — SSE:688506","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":5,"phase_2":2,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}